We should not look at these medications as weak or strong, but consider the needs of each patient individually, she says
A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89)
Results based on a January 2026 analysis of 14,203 Noom GLP-1Rx Program members who actively logged weight over a 40-week period
EX-4 in hGLP-1R mice (n = 57 per group, one-way ANOVA with Bonferroni post-tests)
Of course, with microdosing we would expect less of the gastrointestinal side effects as those effects are dose-dependent, so a lower dose means lower side effects. Many patients interested in microdosing are also interested in short-term GLP-1 drug use, but Dr
Sleep will be important in this process